Publications 2005 - 2017
2017 2016 2015 2014 2013
2012 2011 2010 2009 2008
2007 2006 2005
1. Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario Clinical Oncology Group Lung Cancer. Lung Cancer. 104:65-69, 2017. (DOVE-M)
2. Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary J-P, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C,. Dayes IS, Warde P, Craig TK, Julian JA, Levine MN. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology. [E-pub: 15 Mar 2017] In press. (PROFIT)
back to the top
1. Serrano PE, Gafni A, Gu CS, Gulenchyn KY, Julian JA, Law C, Hendler AL, Moulton CA, Gallinger S, Levine MN. Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial. Journal of Oncology Practice. [E-pub: 21 Jun 2016] 12(7): 686-687, 2016 (e765-e774). (PET CAM)
2. Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, Kaatz S, Schulman S, Connors JM, Ginsberg JS, Spadafora L, Liaw P, Weitz JI, Julian JA. D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. Thrombosis Research. [E-pub: 23 Jun 2016] 146:119-125, 2016. (DODs)
3. Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical Lung Cancer. [E-pub: 3 Oct 2016] In Press.
4. Bates SM, Takach Lapner S, Douketis JD, Kearon C, Julian J, Parpia S, Schulman S, Weitz JI, Linkins LA, Crowther M, Lim W, Spencer FA, Lee AYY, Gross PL, Ginsberg J. Rapid quantitative D-dimer to exclude pulmonary embolism: a prospective cohort management study. Journal of Thrombosis and Haemostasis 14: 504–9, 2016. (SIMPLE)
back to the top
1. Addison CL, Pond GR, Cochrane B, Zhao H, Chia SK, Levine MN, Clemons M. Correlation of baseline biomarkers with clinical outcomes and response to Fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. Journal of Bone Oncology 4:47-53, 2015. (ZAMBONEY)
2. Boekhout A, et al. A Survivorship Care Plan for Breast Cancer Survivors: Extended Results of a Randomized Clinical Trial. Journal of Cancer Survivorship. In Press. (FUP II)
3. Kearon C, Spencer FA, O'Keefe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA, for the D-Dimer Optimal Duration Study Investigators . D-dimer to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy. A cohort study. Annals of Internal Medicine. 162:27-34, 2015 (DODS)
4. Lam K, Scollard DA, Chan C, Levine MN, Reilly RM. Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin). Applied Radiation and Isotopes. 95:135-142, 2015. (PETRA)
5. Lam K, Chan C, Done SJ, Levine MN, Reilly RM. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab. Nuclear Medicine and Biology. [E-pub: 13 Oct 2014] 42:78-84, 2015 (PETRA)
6. Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, Bordeleau L, Pritchard KI. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Journal Clinical Oncology. [E-pub: 23 Nov 2015]. (ONCOTYPEDX)
7. You J, Cline K, Gu C-S, Pritchard KI, Dayes I, Gulenchyn K, Inculet R, Dhesy-Thind S, Freeman M, Chan A, Julian J, Levine M. 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography to Diagnose Recurrent Cancer. British Journal of Cancer. In Press. (PETREC)
back to the top
1. Bane AL, Whelan TJ, Pond GR, Parpia S, Gohla G, Fyles AW, Pignol JP, Pritchard KI, Chambers S, Levine MN. Tumor Factors Predictive of Response to Hypofractionated Radiotherapy in a Randomized Trial Following Breast Conserving Therapy. Ann Oncol. 2014; 25(5):992-8. (HYPO sub-study)
2. Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SK, Dent RA, Song X, Robidoux A, Parpia S, Warr D, Rayson D, Pritchard KI, Levine MN.. Randomised, Phase II, Placebo-Controlled, Trial of Fulvestrant plus Vandetanib in Postmenopausal Women with Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer (MBC). OCOG ZAMBONEY Study. British Cancer Research and Treatment [E-pub: 14 Jun 2014] 146(1):153-162, 2014. (ZAMBONEY)
3. Coyle D, Grunfeld E, Coyle K, Pond G, Julian JA, Levine MN. Cost Effectiveness of a Survivorship Care Plan for Breast Cancer Survivors. Journal of Oncology Practice. 2014; 10(2):e86-e92.  (FUP-2 study)
4. Goodwin P, Segal RJ, Vallis M, Ghadirian P, Ligibel J, Pond GR, Robidoux A, Blackburn GL, Findlay B, Gralow J, Mukherjee SD, Levine MN, Pritchard KI. A Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women with Breast Cancer Receiving Letrozole: The LISA Trial. Journal of Clinical Oncology [E-pub: 16 Jun 2014]  32(21):2231-2239, 2014.(LISA)
5. Moulton C-A, Gu C-S, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith RJ, Jalink DW, Husien M, Serrano PE, Hendler AL, Haider MA, Ruo L, Gulenchyn KY, Finch T, Julian JA, Levine MN, Gallinger S. Effect of PET before Liver Resection on Surgical Management for Colorectal Adenocarcinoma Metastases. A Randomized Clinical Trial. Journal of the American Medical Association 311(18):1863-1869, 2014. (PET CAM)
6. Parpia S, Julian JA, Thabane L, Gu C, Whelan TJ, Levine MN. Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer. BMJ Open [E-pub: 27 Oct 2014] 4(10):1-7, 2014.(RAPID/HYPO)
back to the top
1. Dayes IS, Whelan TJ, Julian JA, Parpia S, Pritchard KI, D'Souza DP, Kligman L, Reise D, LeBlanc L, McNeely ML, Manchul L, Wiernikowski J, Levine MN. A Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women with Breast Cancer. Journal of Clinical Oncology [E-Pub: 16 September 2013] 31(30):3758-3763, 2013. (DELTA)
2. Gulenchyn KY, Singnurkar A, Bordeleau L, Levine MN, Dhamanaskar K, Goodbody A, Valliant J, Cline K. The feasibility, acceptability and safety of Molecular Breast Imaging (MBI) using a breast specific gamma camera and 99mTc-sestamibi in patients with a high risk of breast cancer. 2013 European Association of Nuclear Medicine, Lyon, France European Journal of Nuclear Medicine and Molecular Imaging 40 (Suppl 2): S462, 2013
3. Martin JM, Frantzis J, Chung P, Langah I, Crain M, Cornes D, Plank A, Finch T, Jones M, Khoo E, Catton C. Prostate Radiotherapy Clinical Trial Quality Assurance: How Real Should Real Time Review Be? (A TROG-OCOG Intergroup Project). Radiotherapy and Oncology [E-Pub: 10 June 2013] 107(3):333-338, 2013. (PROFIT)
4. Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT, Kong I, Cochrane B, Nichol A, Roy I, Germain I, Akra M, Reed M, Fyles A, Trotter T, Perera F, Beckham W, Levine MN, Julian JA. Interim Cosmetic and Toxicity Results from RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using 3D Conformal External Beam Radiation Therapy. Journal of Clinical Oncology [E-Pub: 8 July 2013] 31(32):4038-45, 2013. (RAPID)
5. Parpia S, Koval JJ, Donner A. Evaluation of confidence intervals for the kappa statistic when the assumption of marginal homogeneity is violated. Computational Statistics 38: 2709-2718, 2013.
6. Parpia S, Thabane L, Julian JA, Whelan TJ, Levine MN. Empirical Comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: A breast cancer study. BMC: Medical Research Methodology 13:44, 2013.
7. Vedantham S, Goldhaber SZ, Kahn SR, Julian J, Magnuson E, Jaff MR, Murphy TP, Cohen DJ, Comerota AJ, Gornik HL, Razavi MK, Lewis L, Kearon C. Rationale and design of the ATTRACT Study: A multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. American Heart Journal 165:523-530, 2013. (ATTRACT)
back to the top
1. Elit LM, Lee AY, Parpeer S, Swystun LL, Liaw PC, Hoskins P, Julian DH, Julian JA, Levine MN. Dalteparin Low Molecular Weight Heparin (LMWH) in ovarian cancer: A phase II randomized study. Thrombosis Research [E-Pub: 5 Oct 2012] 130:894-900, 2012. (FOCUS)
2. Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, Ramirez L, Julian J. A Randomized Phase II Trial of Apixaban for the Prevention of Thromboembolism in Patients with Metastatic Cancer. Journal of Thrombosis and Haemostasis 10(5):807-14, 2012. (CV-185-027)
3. Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, Hodgson N, Lovrics P, Perera F, Elavathil L, OMalley FP, Down N, Bodurtha A, Shelley W, Levine MN. A Prospective Study of FDG PET in the Assessment of Regional Nodal Spread of Disease in Breast Cancer Patients: An Ontario Clinical Oncology Group (OCOG) Study. Journal Clinical Oncology [E-Pub: 5 Mar 2012] 30(12):1274-9, 2012. (PET PREDICT)
back to the top
1. Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Gu C-S, Kuruvilla MS, Cline KJ, Julian JA, Evans WK, Levine MN. Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial. Journal of Thoracic Oncology 6(8): 1367-1372, 2011.
2. Elit L, Levine MN, Julian JA, Sellors JW, Lytwyn A, Chong S, Mahony JB, Gu C, Finch T, Zeferino LC. Expectant management versus immediate treatment for low-grade cervical intra-epithelial neoplasia: a randomized trial in Canada and Brazil. Cancer. [Epub: 08 Nov 2010] 117(7):1438 - 1445, 2011.
3. Grunfeld E, Julian JA, Pond G, Maunsell E, Coyle D, Folkes A, Joy AA, Provencher L, Rayson D, Rheaume DE, Porter GA, Paszat LF, Pritchard KI, Robidoux A, Smith S, Sussman J, Dent S, Sisler J, Wiernikowski J, Levine MN. Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. Journal Clinical Oncology. [E-Pub: 31 October 2011] 29(36):4755 - 4762, 2011.
4. Parpia S, Julian JA, Thabane L, Lee AYY, Rickles FR, Levine MN. Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism. Contemporary Clinical Trials 32: 829-833, 2011.
5. Pond GR, Abbasi S. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. Clinical Trials 8: 260-269, 2011.
6. Pond GR. Statistical issues in the use of dynamic allocation methods for balancing baseline covariates. British Journal of Cancer 104: 1711-1715, 2011.
7. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine MN. Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios: A randomized trial. Annals of Internal Medicine, 155; 653-659, 2011.
back to the top
1. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of Thrombosis and Haemostasis 8: 1959-1965, 2010.
2. Whelan TJ, Pignol PJ, Levine MN et al. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. N Engl J Med 362:513-520, 2010.
back to the top
1. Couturaud F, Leroyer C, Julian JA, Kahn SR, Ginsberg JS, Wells PS, Douketis JD, Mottier D, Kearon C. Factors That Predict Risk of Thrombosis in Relatives of Patients With Unprovoked Venous Thromboembolism. Chest. 2009 Jul 10. [Epub: 10 Jul 2009] 136(6):1537 - 1545, 2009.
2. Levine MN. New Antithrombotic Drugs: Potential for Use in Oncology. J Clin Oncol 27(29): 4912 - 4918, 2009.
3. Maziuk DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu C, Cline KJ, Evans WK, Levine MN. Positron Emission Tomography in Staging Early Lung Cancer: A Randomized Trial. Annals of Internal Medicine 151:221-228, 2009.
4. OMalley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KP. Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. J Natl Cancer Inst 101:644-650, 2009.
5. Patil N, Crook J, Saibishkumar EP, Aneja M, Borg J, Pond G, Ma C. The effect of obesity on rectal dosimetry after permanent prostate brachytherapy. Brachytherapy 8(2):218-22, 2009.
6. Rana P, Julian J, Levine M. P-selectin ready for prime time? Blood 113(8):1860; author reply 1860-1, 2009.
7. Schnarr K, Boreham D, Sathya J, Julian J, Dayes IS. Radiation-Induced Lymphocyte Apoptosis to Predict Radiation Therapy Late Toxicity in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics 74(5): 1424-30, 2009.
8. Sriharsha L, Lipton JH, Pond G, Ma C, Raybardhan S, Messner HA, Seki JT. Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size. J Oncol Pharm Practice 00:110, 2009.
9. Vidal L, Tsao MS, Pond GR, Cohen EE, Cohen RB, Chen EX, Agulnik M, Hotte S, Winquist E, Laurie S, Neil Hayes D, Ho J, Dancey J, Siu LL. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31(8):1006-1012, 2009.
10. Winquist E, Julian JA, Moore MJ, Nabid A, Sathya J, Wood L, Venner P, Levine M. Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa in Men With Castration-Resistant Prostate Cancer and Anemia. Journal of Clinical Oncology 27(4):644-6, 2009.
back to the top
1. Ceballos KM, Chapman W, Daya D, Julian JA, Lytwyn A, McLachlin CM, Elit L. Reproducibility of the Histological Diagnosis of Cervical Dysplasia Among Pathologists From 4 Continents. International Journal of Gynecological Pathology 2008; 27(1): 101-107.
2. Crump M, Gluck S, T D, Stewart D, Levine M, Kirkbride P, Dancey J, OReilly, S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L and Pritchard KI. Randomized Trial of High-Dose chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared with Standard-Dose Chemotherapy in Women with Metastatic Breast Cancer: NCIC MA.16. Journal of Clinical Oncology 26:37-43, 2008.
3. Dayes IS, Levine MN, Julian JA, Pritchard KI, DSouza DP, Kligman L, Reise D, Wiernikowski JA, Bonilla L, Whelan TJ. Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Res Treat. 110(2):337-42, 2008.
4. Elit LM, Bondy SJ, Paszat LP, Holowaty EJ, Thomas GM, Stukel TA, Levine MN. Surgical outcomes in women with ovarian cancer. Can J Surg 51(5):346-54, 2008.
5. Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron M-J, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and Time Course of the Post-thrombotic Syndrome after Acute Deep Venous Thrombosis, Annals of Internal Medicine 2008; 149: 698-707.
6. Kearon C, Julian JA, Kovacs MJ, Anderson DR, Wells P, Mackinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M, Ginsberg JS; ELATE Investigators. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: Results from a randomized trial. Blood. 2008 Dec 1;112(12):4432-6. Epub 2008 Sep 12.
7. Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ. A phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Research Treatments, March 2008; 108(1): 87-92.
8. Levine MN, Julian JA. Registries That Show Efficacy: Good, but Not Good Enough. J Clin Oncol 26:5316-5319, 2008.
9. Ng R, Pond GR, Tang PA, MacIntosh PW, Siu LL, Chen EX. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Annals of Oncology, March 2008; 19(3): 481-6.
10. ODonnell MJ, McRae1 S, Kahn SR, Julian JA, Kearon C, MacKinnon B, Magier D, Strulovich C, Lyons T, Robinson S, Hirsh J, Ginsberg JS, Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS) - A randomized controlled trial. Thrombosis and Haemostasis 2008; 99, 3: 623-9.
11. OMalley FP, Thomson T, Julian J, Have C, Crosby R, Gelmon K, Andrulis I, Whelan T. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Archives of Pathology & Laboratory Medicine 2008; 132 (1): 61-5.
12. Pond GR, Siu LL, Moore MJ, Oza AM, Hirte H, Winquist E, Goss G, Hudes G, Townsley CA. Nomograms to predict serious adverse events in patients enrolled in phase II clinical trials of moleculary targeted agents. Journal of Clinical Oncology, March 2008; 26(8): 1324-30.
13. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):257S-298S. PMID: 18574268 [PubMed - indexed for MEDLINE]
14. Simunovic M, Goldsmith C, Thabane L, McLeod R, Denardi F, Whelan TJ, Levine MN. The Quality Initiative in Rectal Cancer (QIRC) trial: study protocol of a cluster randomized controlled trial in surgery. BMC Surg. 2008 Feb 15;8:4. PMID: 18279521 [PubMed - indexed for MEDLINE]
back to the top
1. Dayes IS, Levine MN, Julian JA, Pritchard KI, D'Souza DP, Kligman L, Reise D, Wiernikowski JA, Bonilla L, Whelan TJ. Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Res Treat. 2008 Jul;110(2):337-42. Epub 2007 Sep 13. PMID: 17851756 [PubMed - in process]
2. Elit L, Julian JA, Sellors JW, Levine M. Colposcopists' agreement on cervical biopsy site. Clinical and Experimental Obstetrics and Gynecology 2007; 34(2): 88-90.
3. Findlay B, Tonkin K, Crump M, Norris M, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Pritchard KI, Palmer MJ, Tu D and Shepherd L. A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Annals of Oncology 18:1646-1651, 2007.
4. Levine MN. Adjuvant therapy and thrombosis: how to avoid the problem? Breast. 2007 Dec;16 Suppl 2:S169-74. Epub 2007 Aug 27. Review. PMID: 17720502 [PubMed - indexed for MEDLINE]
5. Levine MN, Ganz PA, Haller DG. Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future. Journal of Clinical Oncology 25(6):614-616, 2007.
6. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H. Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D and Francis CW. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer. Journal of Clinical Oncology 25:5490-5505, 2007.
7. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN. Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non-Small-Cell Lung Cancer With Disease-Related Anemia. Journal of Clinical Oncology 25(9):1027-1032, 2007.
back to the top
1. Arnold DM, Julian JA, Walker IR. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over twenty-one years of follow up. Blood 2006; 108: 460-4.
2. Butow PN, Solomon M, Young JM, Whelan T, Salkeld G, Wilson K, Harrison JD, Hruby G, Mansour O, Kennedy N, Tattersall MH. Consumer impact of an interactive decision aid for rectal cancer patients offered adjuvant therapy. Colorectal Dis 2006; 8 (8): 676-682.
3. Charles C, Gafni A, Whelan T, OBrien MA. Cultural influences on the physician-patient encounter: The case of shared treatment decision-making. Patient Educ Couns 2006; 63 (3): 262-267.
4. Dayes IS, Whelan TJ, Julian JA, Kuettel MR, Regmi D, Okawara GS, Patel M, Reiter HI, Dubois S. Cross-border referral for early breast cancer: an analysis of radiation fractionation patterns.  Current Oncology 2006; 13(4): 124-9.
5. Elwyn G, OConnor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R, Barratt A, Barry M, Bernstein S, Butow P, Clarke A, Entwistle V, Feldman-Stewart D, Holmes-Rovner M, Llewellyn-Thomas H, Moumjid N, Mulley A, Ruland C, Sepucha K, Sykes A, Whelan T; International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 2006; 333 (7565): 417.
6.  Feldman-Stewart D, Brennenstuhl S, McIssac K, Austoker J, Charvet A, Hewitson P, Sepucha KR, Whelan T.A systematic review of information in decision aids. Health Expectations 2006; 10:46-61.
7. Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T. Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. Journal of Clinical Oncology 2006; 24: 848-855.
8. Hack TF, Whelan T, Olivotto IA, Weir L, Bultz BD, Magwood B, Ashbury F, Brady J. Standardized audiotape versus recorded consultation to enhance informed consent to a clinical trial in breast oncology. Psycho-Oncology 2006; [Epub ahead of print].
9. Kearon C, Ginsberg JS, Douketis J, Turpie AG, Bates SM, Lee AY, Crowther MA, Weitz JI, Brill-Edwards P, Wells P, Anderson DR, Kovacs MJ, Linkins L-A, Julian JA, Bonilla LR, Gent M, for the Canadian Pulmonary Embolism Diagnosis Study (CANPEDS) Group. An evaluation of D-dimer in the diagnosis of pulmonary embolism. A randomized trial. Annals of Internal Medicine 2006; 144: 812-21.
10. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296 (8): 935-42.
11. Lee AYY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA.  Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer. Journal of Clinical Oncology 2006; 24: 1404-1408.
12. Levine MN and Whelan T. Adjuvant Chemotherapy for Breast Cancer 30 Years Later. New England Journal of Medicine 2006; 355: 1920-1922.
13. Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 2006; 17 (11): 1637-1643.
14. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24 (16): 2437-2443.
15. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN, for the National Cancer Institute of Canada Clinical Trials Group.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New England Journal of Medicine 2006; 354: 2103-2111.
16. Simunovic M, Rempel E, Thriault ME, Coates A, Whelan T, Holowaty E, Langer B, Levine M. Influence of hospital characteristics on patient operative mortality and survival following major cancer surgery in Ontario. Can J Surg 2006; 49 (4): 251-258.
17. Whelan T, Pritchard K. Managing patients on endocrine therapy: Focus on quality-of-life issues. Clin Cancer Res 2006; 12 (3): 1056s-1060s.
18. Wright JR, Bouma S, Dayes I, Sussman J, Simunovic MR, Levine MN, Whelan TJ.   The Importance of Reporting Patient Recruitment Details in Phase III Trials. Journal of Clinical Oncology 2006; 24: 843-845.
19. Verma DK, Shaw DS, Shaw ML, Julian JA, McCollin SA,Tombe K. An evaluation of analytical methods, air sampling techniques, and airborne occupational exposure of metalworking fluids. Journal of Occupational and Environmental Hygiene 2006; 3: 53-66.
back to the top
1. Charles C, Gafni A, Whelan T, OBrien MA. Treatment decision aids: conceptual issues and future directions. Health Expect 8 (2); 114-125, 2005.
2. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, Barone M, Piovella F, Turpie AG, Middeldorp S, van Nguyen P, Prandoni P, Wells PS, Kovacs MJ, MacGillavry MR, Costantini L, Ginsberg JS. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case control study. Journal of Thrombosis and Haemostasis 3 (5); 943-948, 2005.
3. Grunfeld E, Dhesy-Thind S, Levine M for The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). Canadian Medical Association Journal 172; 1319-1320, 2005.
4. Grunfeld E, Zitzelsberger L, Coristine M, Whelan T, Aspelund F, Evans W. Job stress and job satisfaction of cancer care workers. Psycho-Oncology 14 (1); 61-69, 2005.
5. Kahn SR, Kearon C, Julian JA, Mackinnon B, Kovacs MJ, Wells P, Crowther MA, Anderson DR, VAN Nguyen P, Demers C, Solymoss S, Kassis J, Geerts W, Rodger M, Hambleton J, Ginsberg JS; For The Extended Low-Intensity Anticoagulation For Thrombo-Embolism (Elate) Investigators. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. Journal of Thrombosis and Haemostasis 3; 718-723, 2005.
6. Kearon C, Kovacs MJ, Julian JA. Deep vein thrombosis. Lancet 12; 366 (9480); 118; author reply 119-120, 2005.
7. Kovacs MJ, Kearon C, Julian JA, Douketis JD, Demers C, Wells PS, Turpie AG, Anderson DR, Kahn SR, Nguyen PV, Green D, Kassis J, Geerts W, Mackinnon B, Ginsberg JS. Influence of warfarin on symptoms of fatigue: findings of a randomized trial. The Annals of Pharmacotherapy 39 (5); 840-842, 2005.
8. Kovacs MJ, Levine M, Keeney M, MacKinnon KM, Lee AY. Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thrombosis & Haemostasis 93; 1185-1188, 2005.
9. Lee A, Levine M. Treatment of venous thromboembolism in cancer patients. Cancer Control 12: Suppl 1; 17-21, 2005.